Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Adamis Pharmaceuticals’ Tempol shows promise against SARS-CoV-2 in preclinical research

By Brian Buntz | June 3, 2021

AdamisThe investigational drug Tempol from Adamis Pharmaceuticals Corp. (NSDQ:ADMP) could be a potent oral antiviral treatment for COVID-19 based on cell culture research, according to scientists at the National Institutes of Health (NIH). 

The positive research news caused Adamis Pharmaceuticals’ stock to jump 61% from $0.69 to $1.13 today. The quick jump in its stock valuation triggered a trading halt. 

Tempol belongs to a growing class of anti-COVID-19 drugs that aim to stop viral replication. 

Pfizer (NYSE:PFE) is also developing a similar potential COVID-19 treatment known as PF-07321332 that is a protease inhibitor. That investigational drug binds to a viral enzyme known as protease to stop viral replication.

Remdesivir, the subcutaneous injectable drug from Gilead Sciences (NSDQ:GILD) that won FDA approval on October 22, 2020, binds to the RNA polymerase and protease of SARS-CoV-2.  

Tempol relies on a different mode of action. The drug interferes with a viral enzyme known as RNA replicase. 

RNA replicase plays a central role in the genome replication of coronaviruses, including SARS-CoV-2. 

Researchers at NIH discovered that SARS-CoV-2 RNA replicase relies on two iron-sulfur clusters for structural support. A separate group of researchers at the Tracey Rouault Lab within NIH found that TEMPOL degrades iron-sulfur clusters. 

To determine whether TEMPOL is effective in humans will require more research, according to Dr. Tracey Rouault, who leads the aforementioned laboratory. “Given TEMPOL’s safety profile and the dosage considered therapeutic in our study, we are hopeful,” Rouault said in a statement. “However, clinical studies are needed to determine if the drug is effective in patients, particularly early in the disease course when the virus begins to replicate.”

NIH plans on performing animal studies to further gauge the effectiveness of Tempol against COVID-19. 

FDA approved a new investigational new drug application for Tempol as a potential COVID-19 treatment in February.

Adamis has also begun patient enrollment for a Phase 2/3 clinical trial for Tempol.


Filed Under: Infectious Disease, RD
Tagged With: Adamis Pharmaceuticals, coronavirus, covid-19, National Institutes of Health, Pfizer, TEMPOL
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

M&A Merger and acquisition business finance concept. Businessman pressing button.
25-plus years of Big Pharma megadeals
pharma R&D | molecule model
Are Big Pharma giants getting the right ROI on their R&D investments? A visual exploration
The pizza box problem — and why it might kill everything from Teflon to drugs
Cleveland
Ohio grows into a globally recognized R&D hub
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE